Narendra D. Lalwani, Ph.D., FAHA, DABT
2018
Compensation breakdown
| Non-Equity Incentive Plan | $43,000 |
|---|---|
| Option Awards | $1,860,071 |
| Salary | $430,000 |
| Other | $12,250 |
| Total | $2,345,321 |
DABT received $1.9M in option awards, accounting for 79% of the total pay in 2018.
DABT also received $43K in non-equity incentive plan, $430K in salary and $12.3K in other compensation.
Rankings
In 2018, Narendra D. Lalwani, Ph.D., FAHA, DABT's compensation ranked 4,947th out of 14,244 executives tracked by ExecPay. In other words, DABT earned more than 65.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,947 out of 14,244 | 65th |
Division Manufacturing | 1,862 out of 5,759 | 68th |
Major group Chemicals And Allied Products | 682 out of 2,122 | 68th |
Industry group Drugs | 571 out of 1,811 | 69th |
Industry Pharmaceutical Preparations | 438 out of 1,385 | 68th |
Pay ratio
| Narendra D. Lalwani, Ph.D., FAHA, DABT's Pay | $2,345,321 |
|---|---|
| Median Employee's Pay | $601,814 |
| Pay Ratio | 4to 1 |
In 2018, the annual total compensation of Narendra D. Lalwani, Ph.D., FAHA, DABT was $2,345,321.
The annual total compensation of the median employee at Esperion Therapeutics was $601,814.
The ratio of Narendra D. Lalwani, Ph.D., FAHA, DABT's pay to the pay of median employee was therefore 4 to one.
DABT's colleagues
We found three more compensation records of executives who worked with Narendra D. Lalwani, Ph.D., FAHA, DABT at Esperion Therapeutics in 2018.